N-Acetyl Cysteine (NAC) for Lung Function
NAC is the best-evidenced supplement for chronic lung conditions — it reduces COPD exacerbations as a mucolytic and glutathione precursor.
Overview
Verdict
The 523-participant BRONCUS trial found NAC did not slow FEV1 decline and did not reduce exacerbations overall in COPD; only a subgroup not using inhaled corticosteroids showed fewer exacerbations.
How It Works
Downstream effects
Dosing & Protocol
Doses used in human trials
| Population | Dose | Schedule | Notes |
|---|---|---|---|
| BRONCUS trial regimen | 600 mg | Once daily for 3 years | Did not slow FEV1 decline or reduce exacerbations overall |
| Mucolytic use in chronic bronchitis | 600 mg | Once or twice daily | Targets sputum viscosity and exacerbations, not lung function |
| Higher-dose respiratory arms | 600 mg | Twice daily | 1,200 mg per day; used where exacerbations are frequent |
| Effervescent formulation | 600 mg in water | Once or twice daily | Extra fluid supports the mucolytic effect |
No dose of NAC has been shown to preserve forced expiratory volume in COPD.
Simple protocol
- 1
Do not use NAC to protect lung function
The trial that tested exactly that found no effect on FEV1 decline over three years.
- 2
Prioritise what does change the trajectory
Smoking cessation, inhaled therapy, pulmonary rehabilitation and vaccination are the interventions with real effects on lung function.
- 3
Consider NAC only for mucus and exacerbations· 6-12 months
600 mg once or twice daily is the mucolytic regimen, and that is a symptom and exacerbation claim.
- 4
Discuss it with your respiratory team
Especially relevant given the subgroup finding involved people not on inhaled corticosteroids.
- 5
Stop if wheeze worsens
Bronchospasm has been reported in susceptible individuals.
- 6
Review honestly at 6 months
Judge by sputum and exacerbation counts, since spirometry is unlikely to change.
Evidence
Studies linked to this pairing.
Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomised placebo-controlled trial
Decramer M, Rutten-van Molken M, Dekhuijzen PN +9 more
N-acetylcysteine did not slow the decline in FEV1 and did not reduce exacerbation rates overall.
- FEV1 decline
- Not slowed by NAC versus placebo
- Exacerbation rate
- No overall reduction
- Subgroup signal
- Fewer exacerbations in participants not using inhaled corticosteroids
- Participants
- 523 in the BRONCUS randomised trial
- Dose and duration
- 600 mg daily over three years
- Main limitation
- The subgroup finding is exploratory and should not be treated as a positive result
Safety
This is a negative result for lung function
NAC did not slow the decline in FEV1 in a three-year randomised trial. Do not use it in place of inhaled therapy, vaccination, pulmonary rehabilitation or stopping smoking.
Interactions & Conflicts
Interactions and cautions
| Interacts with | Severity | Mechanism | Action |
|---|---|---|---|
| Asthma | moderate | Bronchospasm reported in susceptible individuals | Start at 600 mg once daily and stop if wheeze worsens |
| Inhaled corticosteroids | low | Subgroup benefit appeared only in those not using them | Do not stop prescribed inhaled therapy to take NAC |
| Anticoagulants and antiplatelet drugs | moderate | Possible additive effect on platelet aggregation | Discuss with a prescriber; stop two weeks before surgery |
| Nitroglycerin and nitrates | moderate | Enhanced vasodilation | Risk of hypotension and severe headache |
| Oral antibiotics | low | Theoretical reduction in absorption when co-administered | Separate doses by about two hours |
| Cystinuria | moderate | Increased urinary cysteine load | Avoid unless supervised |
References
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.